LYEL
Lyell Immunopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LYEL
Lyell Immunopharma, Inc.
A clinical‑stage T-cell reprogramming company that develops curative cell therapies for solid tumors
201 Haskins Way, South San Francisco, California 94080
--
Lyell Immunopharma, Inc., was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company that is expected to enter pivotal trials in 2025 and advance a proprietary next-generation pipeline of autologous chimeric antigen receptor T cell product candidates for patients with hematological malignancies and solid tumors. The company is pioneering new methods aimed at generating T cells that drive durable clinical responses. The patient's living cells are the starting point for the company's investigational CAR T cell therapy, which the company enhances with innovative CAR structures, technologies and manufacturing protocols.
Company Financials
EPS
LYEL has released its 2025 Q2 earnings. EPS was reported at -3.67, versus the expected -3.52, missing expectations. The chart below visualizes how LYEL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LYEL has released its 2025 Q3 earnings report, with revenue of 15.00K, reflecting a YoY change of -55.88%, and net profit of -38.85M, showing a YoY change of 12.87%. The Sankey diagram below clearly presents LYEL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
